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Sustained improvement in left ventricular function and
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ABSTRACT One hundred eighty-eight patients with acute myocardial infarction were studied pro-
spectively from August 1980 to September 1982. One hundred thirty-six of these patients were entered
into a intracoronary streptokinase study after informed consent was obtained. The remaining 52
patients, who either met exclusion criteria for the study or refused to participate, served as a control
group and were treated as those in the study group except that they did not undergo emergency cardiac
catheterization. Left ventricular function was determined in both groups by gated radionuclide ejection
fraction (EF) on admission to the hospital, at discharge, and 6 months after discharge. With successful
reperfusion up to 18 hr after onset of chest pain, mean left ventricular function in the study group
improved (EF 39 + 13% on admission and 46 + 12% at discharge; p < .001). Mean EF in control
patients and those not achieving reperfusion did not change from admission to discharge. Mean EF at 6
month follow-up was not significantly different than at discharge in the study group or the control
group. Total cardiac mortality in the control group was 19% compared with 10% in the study group (p
= .06, NS). When patients admitted in pulmonary edema or shock (Killip class III or IV) were
excluded from both groups, total cardiac mortality in the study group was significantly lower (4%)
compared with in the control group (12.5%, p < .05). The administration of intracoronary streptoki-
nase during evolving myocardial infarction up to 18 hr after onset of chest pain may result in decreased
mortality and sustained improvement in left ventricular function.
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STANDARD CURRENT THERAPY for acute myo-
cardial infarction entails prevention or treatment of
complications secondary to evolving myocardial ne-
crosis. Mortality during the first 30 days after acute
myocardial infarction has been reported to be between
16% and 30% in large series and no definite decrease
in this rate was noted between 1960 and 1975.14 Al-
though there is no universally accepted method for re-
ducing myocardial damage, emergency aortocoronary
bypass surgery has been reported to decrease mortal-
ityl'6 in certain patients. Intracoronary streptokinase
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has been shown to be effective in lysing intracoronary
thrombus and restoring blood supply to jeopardized
myocardiumduring evolving myocardial infarction.7-'0
In reports of small series of patients, reperfusion with
intracoronary streptokinase has induced improvement
in left ventricular function by the time of hospital dis-
charge.9-3 This report presents the first substantial data
from a single center on the effects of intracoronary
streptokinase therapy on mortality and left ventricular
function at long-term follow-up.
Methods
Patients. We prospectively studied 188 consecutive patients
with acute myocardial infarction between August 1980 and Sep-
tember 1982. One hundred thirty-six of these patients were
entered into the streptokinase therapy protocol after informed
consent was obtained. Fifty-two patients who either met exclu-
sion criteria or refused to participate served as controls and were
studied by noninvasive methods. Exclusion criteria for the pro-
tocol included (1) greater than 18 hr elapsed time between onset
of chest pain and evaluation for study entry, (2) history of
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streptokinase allergy, (3) recent (within 2 months) cerebrovas-
cular accident, (4) recent (within 2 weeks) surgery, or (5) evi-
dence of significant valvular disease. The characteristics of the
patient population are listed in table 1 and specific reasons for
entry of patients into the control group are listed in table 2.
Study protocol. The diagnosis of myocardial infarction was
made by a typical history of prolonged severe chest pain com-
bined with characteristic electrocardiographic findings of injury
current in two adjacent leads with reciprocal ST changes. In all
patients diagnostic creatine kinase elevation evolved, with posi-
tive MB fraction determinations. The patients were stabilized in
the emergency room before being transported to the cardiac
catheterization laboratory. All patients received intravenous li-
docaine prophylactically.
In the first 17 patients studied, radionuclide and angiographic
ejection fraction determinations were made immediately before
and up to 4 hr after streptokinase administration. There was no
significant change in ejection fraction after cardiac catheteriza-
tion, even in patients who had successful thrombolysis.9' 10 In
the remaining patients, thallium images were obtained before
coronary arteriography with the intravenous injection of 1.5 to 2
mCi of thallium 201, as described previously.10
Thallium scintigraphy should not be immediately preceded
by gated radionuclide ventriculography. We felt that thallium
imaging would provide useful information on the success of
reperfusion and would also aid in localization of the infarct-
related artery. Since there was no change in left ventricular
function from hospital admission thru postcatheterization in the
initial 17 patients, we felt that it was reasonable to perform
ventriculography after reperfusion thallium imaging on admis-
sion of patients to the coronary care unit.
The majority of patients underwent right heart catheterization
with a balloon-tipped thermodilution catheter and insertion of a
temporary transvenous pacemaker. Coronary arteriography was
first performed in the presumed infarct-related artery. If a total
occlusion was demonstrated in this artery intracoronary nitro-
glycerin was administered (100 to 300 ,ug into the right coro-
nary artery; 300 to 500 ,ug into the left coronary artery). If
reperfusion was not achieved by nitroglycerin -administration,
then a 10,000 U bolus of streptokinase (250,000 U of streptoki-
nase dissolved in 100 ml normal saline; Streptase, Hoeschst-
Roussel Pharmaceuticals Inc.) was followed by a 2000 U/min
infusion. Coronary arteriography was repeated every 15 min to
assess progress in thrombolysis. The first 60 patients in the
series (group A) underwent streptokinase infusion for a total
period of 60 min or less and in 25 of these patients clot perfora-
tion by a 0.032 inch guidewire (Surgimed Inc.) was attempted.
Thirteen of these patients also underwent subselective strepto-
TABLE 1
Patient population
Study group p Control groups
No. of patients 136 52
Age (yr) 55+12 <.02A 62+15
Average age of
patients who died 68 +9 NSA 67 10
(n = 17) (n= 11)
Previous MI 20 NS 11
History of CHF 6 NS 5
Anterior MI 69 NS 29
Shock or pulmonary
edema on admission 11 NS 4
MI = myocardial infarction; CHF congestive heart failure.
TABLE 2
Reasons for patient entry into control group
Reason n
Diagnosis of MI > 18 hr from onset of chest pain 15
Refused study 10
Age > 70 (in first 60 patients evaluated) 10
History of recent CVA 8
Recent surgery 4
Valvular disease 2
Vascular access not achieved 2
Bleeding disorder 1
Total 52
MI = myocardial infarction; CVA = cerebrovascular accident.
kinase infusion by a small perfusion catheter (American Ed-
wards or USCI) that was inserted through the larger angiograph-
ic catheter. After reevaluation of the protocol, the subsequent 76
patients (group B) underwent infusions up to 90 min long in an
attempt to increase the reperfusion rate; intracoronary guidewire
manipulation was not performed in patients in this group. Two
patients in group B underwent subselective streptokinase ad-
ministration after 90 min of ostial streptokinase failed to pro-
duce thrombolysis. No additional benefit was achieved by sub-
selective streptokinase administration.
At the termination of streptokinase infusion, repeat coronary
arteriography was performed in the infarct-related vessel and in
the remaining coronary artery. If the patients were hemodynam-
ically stable, a biplane left ventricular cineangiogram was per-
formed with 20 to 40 ml of sodium diatrizoate (Hypaque 76,
Winthrop). After completion of the procedure the arterial
sheath, the pulmonary artery catheter, and the pacing catheter
were left in place for a minimum of 24 hr. Delaying removal of
these catheters reduced the incidence of local bleeding and
hematoma formation after streptokinase administration. After
return to the coronary care unit, delayed thallium redistribution
images were obtained by a method described previously and
analyzed quantitatively.10 Gated radionuclide left ventricular
angiograms were then performed with 99mTc-labeled red blood
cells, as described previously.9' 10 The radionuclide ejection
fraction determinations were repeated 10 days after admission
and at 6 months after hospital discharge. Processing of each
ventriculogram was performed by two technicians independent
of the catheterization team and of each other. Discordant results
were resolved by consensus. As previously noted,9 ejection
fraction values determined by gated ventriculography agreed
well (r = .92) with those determined angiographically. Gated
radionuclide ejection fraction variability in our laboratory was
±6% at the 95% confidence level.
Two patients received intra-aortic counterpulsation. In one,
the indication was pulmonary edema and cardiogenic shock
after successful reperfusion. The second patient had cardiogenic
shock before initiation of thrombolytic therapy for an inferior
myocardial infarction. Both patients survived and have been
discharged from the hospital. No patients in the control group
received intra-aortic counterpulsation. Due to previous reports
of poor results with this treatment in the setting of myocardial
infarction, we felt that it should be reserved for those patients
who had a good chance of successful reperfusion and who were
in cardiogenic shock.
Excluding emergency cardiac catheterization, the control
group and the study group were comparable in their use of
parenteral nitroglycerin, ,3-blockers, and calcium antagonists.
In both groups gated radionuclide ejection fractions were deter-
mined within 24 hr of admission to the hospital, at discharge,
CIRCULATION
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and 6 months after discharge. All ejection fraction data reported
were obtained by gated ventriculography. Ejection fraction and
average demographic data were analyzed by two-tailed paired
and nonpaired Student's t tests. A chi-square analysis was per-
formed on group data, as noted in table annotations. Statistical
significance was accepted at p , .05. Odds ratio calculations
were performed to predict probability of survival for the study
population compared with the control population.
Results
As demonstrated in figure 1, 74% of the 136 patients
in the study group had sustained total occlusion of the
infarct-related artery. The coronary arteries in four
patients in this group were partially reperfused by in-
tracoronary nitroglycerin and residual thrombus was
further cleared by intracoronary streptokinase adminis-
tration. Sixty-nine patients demonstrated reperfusion,
yielding an overall reperfusion rate of 73% after intra-
coronary streptokinase alone. Twenty-seven patients
(27%) failed to demonstrate reperfusion after either
nitroglycerin or streptokinase. Thirty-six patients had
a subtotal occlusion associated with acute transmural
myocardial infarction. Of these, three had unequivocal
coronary spasm superimposed on a fixed stenosis. The
majority of those in the nonthrombotic infarct group
had a severe proximal stenosis with slow antegrade
flow. Of the remaining patients, one had diffuse dis-
ease with no discrete infarct-related lesion and one
patient had normal coronary arteries.
Those patients with coronary occlusion who had
successful thrombolysis demonstrated a significant (p
< .001) improvement in mean left ventricular ejection
fraction from 39 + 13% to 46 ± 12% by the time they
were discharged from the hospital (table 3). Patients in
the control group and those with thrombosis who failed
to reperfuse had no change in mean left ventricular
function from the time of admission through the time
of hospital discharge.
The optimal timing for medical or surgical reperfu-
sion is immediatey after total occlusion. There have
been no conclusive studies to determine the maximum
allowable amount of time between onset of pain and
successful reperfusion. To evaluate this problem, we
grouped the patients in whom reperfusion was
achieved into those presenting 0 to 6 hr, 6 to 12 hr, and
12 to 18 hr from onset of pain. Each group demonstrat-
ed a significant increase in mean ejection fraction from
admission to hospital discharge (figure 2), with greater
increases usually occurring in those patients admitted
with an abnormal ejection fraction. Fifty-eight percent
of patients admitted with ejection fractions of less than
50% had significant (greater than 2 SDs of intrinsic
variability) increases in ejection fraction by the time of
hospital discharge.
There was a slight increase in mean left ventricular
function in the control group that was not statistically
significant. Several patients in the control group had an
increase in ejection fraction by the time of hospital
discharge, but an equal number experienced a signifi-
cant fall in ejection fraction. Although the number of
patients studied 12 to 18 hr after the onset of chest pain
is small, none had a significant fall in ejection fraction,
while 40% had a significant increase. These data sug-
gest that some patients may benefit from reperfusion
up to 18 hr after onset of chest pain.
Left ventricular function 6 months after myocardial in-
farction. Forty-five patients who had successful coro-
nary reperfusion and 11 control patients have returned
for follow-up radionuclide angiograms 6 months after
their myocardial infarction. There was a significant
increase in ejection fraction from admission through
discharge in the reperfusion group. Although the fol-
low-up ejection fraction was slightly lower than that at
discharge, this difference was not significant. Also,
the follow-up ejection fraction was significantly higher
than that on admission (p < .05; table 4). The left
ventricular function in the control group was not sig-
Patients with Acute Ml
N = 136
Reperfusion
NTG + Sk
Li A JAOt \
Coronary Spasm Severe Proximal Other
+ Fixed Stenosis Stenosis N=2 (6%)
N = 3 (8%) N = 31 (86%)
1nts)N = 4 (4%) Reperfusion-SK No Reperfusion (2 % of all patients) (23% of all patie
N = 69 (69%) N = 27 (27%)
FIGURE 1. Coronary anatomic characteristics in 136 patients with acute myocardial infarction.
Vol. 68, No. 1, July 1983 133
 by guest on July 26, 2016http://circ.ahajournals.org/Downloaded from 
SMALLING et al.
TABLE 3
Ejection fractions (EFs, mean + SD) on admission to and discharge
from hospital
Sample Admission Discharge
Group size EF (%) pA EF (%) AEF
Reperfusion 65 39+13 <.001 46±12 7±8
Group A 28 42±16 <.001 51± 13 9±8
Group B 37 36 ± 9 <.001 43 ± 10 6± 7
Noreperfusion 19 41+17 NS 43±18 2±5
Control 48 43±13 NS 43±13 0±5
ABy Student's t test.
nificantly different at follow-up compared with at dis-
charge.
Approximately 38% of all patients entering the pro-
tocol underwent coronary artery bypass surgery before
their discharge from the hospital. Bypass surgery was
performed in patients with significant three-vessel dis-
ease, in those with isolated left anterior descending
coronary artery disease with significant return in func-
tion in the infarct area, or in those who had significant
angina and were on maximal drug therapy. One might
anticipate that the effect of coronary artery bypass sur-
gery would influence return of left ventricular function
and sustain ejection fraction improvement at late fol-
low-up. In those patients in whom 6 month follow-up
data were available, 17 patients had coronary artery
bypass surgery and 28 were treated medically. Inter-
estingly, the ejection fraction on admission was essen-
tially equal and follow-up ejection fractions were also
equal, with significant improvement at follow-up com-
pared with on admission. Although the initial improve-
=
IL.
LU
1
ment in ejection fraction was slightly but not signifi-
cantly higher in the bypass surgery patients compared
with the medically treated patients at hospital dis-
charge, this enhanced improvement was not sustained
through follow-up. Even in patients admitted with
ejection fractions of less than 45%, bypass surgery did
not appear to have a significant effect on changes in
resting left ventricular function at late follow-up. One
patient in the bypass group had a perioperative myo-
cardial infarction and his data were excluded from
comparisons.
Comparison of mortality rates in the study and control
groups. In the 136 patients entered into the streptoki-
nase protocol, there have been 17 deaths. One death
occurred in the cardiac catheterization laboratory in a
patient admitted with pulmonary edema and progres-
sive hypotension. Eight of the 17 had sustained a pre-
vious myocardial infarction and nine were either in
overt pulmonary edema (characteristic radiographic ap-
pearance, orthopnea, and pulmonary capillary wedge
pressure greater than 25 mm Hg) or cardiogenic shock
(blood pressure less than 80 mm Hg systolic) on admis-
sion. Admission status and other demographic character-
istics of patients who died are listed in table 5.
Eleven patients in the control group died. Four of
these had pulmonary edema on admission (by same
criteria used in study group) and two had possibly had
previous myocardial infarctions. The mean age of the
control group was slightly higher than that of the study
group. Other than a small difference in average age,
differences between the groups were not statistically
significant. The average age of those patients who died
40±12 47±11 37±12 45±11 43±17 48±17 43 13 44±13
EF (mean ± SD)
FIGURE 2. Ejection fraction on admission to the hospital (A) and at discharge (D) in patients who underwent reperfusion 0 to 6,
6 to 12, and 12 to 18 hr after onset of pain and in control patients (p by paired Student t test).
I
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TABLE 4
Ejection fraction (EFs, mean + SD) in patients who underwent
successful coronary reperfusion 6 months after myocardial infarc-
tion
Admis- Dis- Follow-
Sample sion charge up
Group size EF (%) pA< EF (%) pA EF (%)
All patients 45 39+14 .001 47+12 NS 45±15
Medical therapy 28 38±14 .001 46±11 NS 45±14
CAB 17 40±14 .001 49 ±13 NS 45 ±17
Medical therapy
(admit. EF < 45%) 20 31±9 .001 42 ± 10 NS 41±14
CAB
(admit. EF < 45%) 11 32 ±9 .001 41±7 .05 37 ± 13
ABy student's t test.
in both groups was comparable (67 to 68 years).
It is interesting to note that only five deaths occurred
in those patients who had successful reperfusion and
only one of these five was a cardiaL death. This patient
presented with an inferior myocardial infarction and
had successful reperfusion of a totally occluded right
coronary artery. He had residual subtotal left anterior
descending coronary artery occlusion, previous anteri-
or myocardial infarction, and 100% circumflex occlu-
sion. Although his initial ejection fraction was 49%, he
developed heart failure on day 3 and died during at-
tempted emergency bypass surgery. Other noncardiac
deaths in the study group included those from anoxic
brain death secondary to prehospital cardiac arrest,
pulmonary embolism 10 months after hospital dis-
charge, sepsis after gastrointestinal surgery 3½/2
months after myocardial infarction, and embolic cere-
brovascular accident.
One patient in group A and one in group B (see
Study protocol) who had pulmonary edema on admis-
sion have survived. Patient No. 110 had pulmonary
edema with an arterial partial pressure of oxygen of 44
mm Hg on hospital admission. He had sustained a
large anterior myocardial infarction and had an ejec-
tion fraction of 17%. His left anterior descending coro-
nary artery was completely occluded at its origin. The
circumflex artery was severely stenosed, with a 95%
proximal lesion, and the right coronary artery was
completely occluded. The patient had successful re-
perfusion after 75 min of streptokinase infusion. After
the reperfusion, a percutaneous intra-aortic balloon
was inserted and he became hemodymically stable. He
underwent bypass surgery on the fifth day after myo-
cardial infarction and is doing well at home 6 months
later, with an ejection fraction of 50%.
As described above, group A consisted of the first
60 patients in the streptokinase series; they were treat-
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ed with a streptokinase infusion of 2000 U/min for 60
min or less. Many of these patients were treated with
intracoronary guidewire manipulation and/or subselec-
tive streptokinase infusion. Group B consisted of the
subsequent 76 patients who were treated with a strepto-
kinase infusion at 2000 U/min for up to 90 min. None
of these patients underwent guidewire manipulation
and only two had subselective streptokinase infusion
after failure of ostial reperfusion.
On admission to the hospital there were fewer (and a
smaller percentage of) control patients who were in
Killip class III or IV compared with in the study group.
Consequently, we examined total and cardiac mortal-
ity rates in all patients except those in cardiogenic
shock or with pulmonary edema on admission. The
total mortality rate in group B compared with that in
control patients demonstrated a threefold increase in
probability of survival, which was statistically signifi-
cant (p < .03; table 6). Although there was an almost
twofold increase in probability of survival in the entire
study group (including patients in cardiogenic shock or
pulmonary edema) when compared with control pa-
tients, this increase was not significant statistically.
When the patients in shock or with pulmonary edema
were excluded, the cardiac mortality rate in the strepto-
kinase-treated group demonstrated a threefold increase
in probability of survival when compared with the con-
trol group. This difference was even more striking in
group B, with an almost tenfold increase in probability
of survival compared with control; this difference was
significant (p < .01).
The mortality rate was inversely related to the reper-
fusion rate. The mortality in group A (18%, associated
with a reperfusion rate of 67%) was insignificantly
greater than the 8% in group B (reperfusion rate of
79%).
TABLE 5
Characteristics of patients who died
Study group Control group
Total % Total %
Total no. of deaths 17 100 11 100
Cardiogenic shock
on admission 2 12 1 9
Pulmonary edema
on admission 8 47 4 36
Anterior MI 9 53 8 73
History of previous MI 8 47 2 18
In-hospital deaths 15 88 (11) 7 67 (14)
Cardiac death
after reperfusion 1 6 (1.4)
Values in parentheses are percentages of total patient population.
135
 by guest on July 26, 2016http://circ.ahajournals.org/Downloaded from 
SMALLING et al.
TABLE 6
Effect of streptokinase therapy on mortality rate
Total mortality Cardiac mortality Cardiac mortality rate
rate rate in class I and 11
Odds Odds Odds
Group Total % ratio pA Total % ratio pA Total % ratio pA
Study group 17/136 12.5 1.88 NS 13/136 9.6 2.55 .06 (NS) 5/125 4 3.43 <.04
Group A 11/60 18.3 1.20 NS 8/60 13.3 1.55 NS 4/55 7.3 1.82 NS
Group B 6/76 7.9 3.13 <.03 5/76 6.6 3.38 <.03 1/70 1.4 9.86 <.01
Control group 11/52 21.2 10/52 19.2 6/48 12.5
Odds ratio = probability of survival compared with control.
ABy chi-square analysis.
In order to further evaluate the effect of age on
mortality in our study, we analyzed data from patients
who were 65 years old or younger in both the study and
control groups. In these patients (109 streptokinase
patients and 28 control patients) there is no difference
in age between the groups, the mean being 51 + 9
years in both. As demonstrated by table 7, the cardiac
mortality rate in the streptokinase-treated patients who
were 65 years old or less was 4.6% compared with
14% in the control group; this difference did not reach
statistical significance (p = .06). In group B, howev-
er, the mortality rate was 3.2%, which was significant-
ly less than that in the control group (14.3%). Thus,
eliminating the possible deleterious effect of age on
mortality rate, there remains a significant decrease in
mortality in patients treated with intracoronary strepto-
kinase therapy as compared with controls.
Complications with intracoronary streptokinase therapy.
Although four deaths were associated with intracoro-
nary streptokinase therapy, none could be directly as-
cribed to it. One patient died in the catheterization
laboratory while in cardiogenic shock. Two other pa-
tients died during emergency surgery after unsuccess-
ful reperfusion. All three of the aforementioned pa-
tients had extremely poor left ventricular function and
TABLE 7
Effect of streptokinase therapy on cardiac mortality rate in patients
65 years old or younger
Average Cardiac mortality rate
age Odds
Group (yr)B Total % ratio pA
Study group 51+9 5/109 4.6 3.47 .061 (NS)
Group A 3/46 6.5 2.39 NS
Group B 2/63 3.2 5.05 .046
Control group 51+9 4/28 14.3
Odds ratio = survival compared to control.
ABy chi-square analysis.
BMean + SD.
136
all had had previous myocardial infarctions. One pa-
tient sustained an embolic cerebrovascular accident
during catheter manipulation around the right coronary
ostium. This patient had an anterior myocardial infarc-
tion with successful reperfusion of the left anterior
descending coronary artery. She subsequently died
after an iatrogenic cerebrovascular accident. Her death
must be considered a complication of cardiac catheter-
ization that may or may have not been exacerbated by
streptokinase. No patients died as a result of blood loss
in this series and bleeding complications were mini-
mal, with only five patients requiring transfusion;
these complications are listed in table 8.
Discussion
Since it has been established that coronary thrombo-
sis is frequent in myocardial infarction, thrombolytic
reperfusion, if performed early enough, should be an
effective method of achieving myocardial salvage. Un-
fortunately, intravenous thrombolytic therapy has not
been established as an efficacious method of achieving
improved survival,'4 15 and no long-term studies have
been performed to determine its effect on left ventricu-
lar function.
Our results demonstrate that intracoronary strepto-
kinase infusion during acute myocardial infarction sig-
nificantly preserves left ventricular function and im-
proves survival compared with that in nontreated
control patients, thereby suggesting significant myo-
cardial salvage. These results are sufficiently impor-
tant to warrant discussion of possible bias influencing
the data.
All patients admitted to our hospital with acute myo-
cardial infarction and who met our preestablished cri-
teria were entered into the streptokinase protocol con-
secutively without clinical selection and therefore
without the bias inherent in such selection. There was
no significant difference between the study and control
groups in incidence of anterior myocardial infarction
CIRCULATION
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TABLE 8
Complications associated with intracoronary streptokinase therapy
n %
Bleeding complications
Hematemesis 5 3.7
Bleeding or hematoma at cath. site 6 4.4
Bleeding at other arterial puncture site 1 0.7
Bleeding after percutaneous balloon-pump
removal (patient heparinized) 2 1.5
Total bleeding complications 14 10.3
Total no. of patients requiring transfusion 5 3.7
Deaths from bleeding 0 0.0
Other complications
Bradycardac arrest 1 0.7
Ventricular fibrillation (during angiography) 3 2.0
Embolic CVA during catheter manipulation
(subsequent late death) 1 0.7
Death in cath. lab secondary to
cardiogenic shock 1 0.7
Death during emergency surgery after
unsuccessful reperfusion 2 1.5
Total deaths associated with intracoronary
streptokinase therapy 4 3.0
CVA = cerebrovascular accident.
or incidence of shock or pulmonary edema on admis-
sion. Although the control group mean age was slight-
ly but significantly higher than that in the study group,
the average age of patients who died in both groups
was not different. Restricting comparison of cardiac
mortality to patients 65 or younger eliminated possible
age bias (mean age of study group = control group -
51 + 9). In this subgroup, intracoronary streptokinase
resulted in a statistically significant reduction in mor-
tality rate in group B and in the entire study group the
reduction approached significance (p = .06). The total
control group mortality rate at up to 2 years follow-up
is not excessive at 21%.
As stated earlier, mortality rate in comparable
groups at 30 days after myocardial infarction ranges
between 15% and 30%. For example, in the European
collaborative study of intravenous streptokinase,'5 the
average mortality rate at 6 months was 30% in the
untreated control group. A recent report of 105 patients
treated for initial myocardial infarction between 1971
and 1978 found an overall in-hospital mortality rate of
13%, with patients who had an anterior myocardial
infarction having a higher mortality rate (15.6%) than
did those with inferior infarcts (9.1%).16 We would
anticipate a slightly higher in-hospital mortality rate
in our series since patients with previous myocardial
infarctions were included, but the rate in our control
group was 15%. It is therefore unlikely that better
survival in the streptokinase group was due to
an excessive mortality rate in the control group.
The benefits of intracoronary streptokinase therapy
in reducing mortality depend on achieving adequate
reperfusion rates. The cardiac mortality rate for the
total study group approaches statistical significance
when compared with that in the control group, with an
increased probability of survival greater than 2.5. The
mortality rate in group B, with a higher reperfusion
rate (79%), is consistently significantly less than in the
control group whether one studies total mortality, car-
diac mortality, or cardiac mortality in Killip class I and
II patients only.
The difference in reperfusion success (67% vs 79%)
and in mortality rates between group A and group B
may reflect a learning curve in the use of intracoronary
streptokinase for the treatment of acute myocardial
infarction. We have modified our methods during the 2
years of the study in order to improve our reperfusion
rates. The use of the intra-aortic balloon in patients
who are hemodynamically unstable after successful
reperfusion may be a further step in achieving a favor-
able outcome. Clot perforation with the 0.032 inch
guidewire may be associated with plaque disruption
and irreversible coronary occlusion. Sixteen of 25 at-
tempts at guidewire clot perforation were successful.
In nine of these, coronary reperfusion was achieved by
the end of the procedure. In five patients, however,
transient opening of the vessel was followed by perma-
nent reclosure. Two patients did not demonstrate re-
perfusion after clot perforation. We have eliminated
this technique from our therapeutic protocol because
initial success in clot perforation by a guidewire often
did not lead to lasting patency.
Previous reports have established that mean left ven-
tricular function does not change in patients with
evolving myocardial infarction from their admission to
the hospital through discharge.9' 10, 17, 18 We designed
our protocol to look prospectively at the effects of
intracoronary streptokinase therapy on myocardial
function (both at hospital discharge and follow-up) in
all consecutive patients meeting admission criteria,
thereby avoiding bias due to patient selection. The
effectiveness of late reperfusion in relation to onset of
infarction in human beings is not known. In animals,
reperfusion at 2 to 3 hr after complete occlusion has
been shown to result in significant return in function in
border zones surrounding an area of myocardial necro-
SiS. 19 20 Clearly, the earlier reperfusion is achieved the
greater the possible benefits. Yet, in humans with
chronic coronary stenosis, some degree of collaterali-
zation may be present that may alter the time course of
necrosis. We therefore designed our protocol to accept
137Vol. 68, No. 1, July 1983
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patients with an onset of chest pain of up to 18 hr
before initiation of therapy in order to answer this
question without preconceived bias. There was no sig-
nificant difference in mortality between the 0 to 6 hr
group and the 6 to 18 hr group. Also, statistically
significant improvement in global left ventricular
function was seen in each of the reperfusion subgroups
(O to 6 hr, 6 to 12 hr, and 12 to 18 hr) and no significant
improvement was observed in the control group. How-
ever, not all patients who had successful reperfusion
had improved global left ventricular function, even
when they underwent reperfusion early after onset of
chest pain. Regional wall motion changes were not
examined by this study and, as reported by other inves-
tigators,12, 13, 21 some return of function may occur re-
gionally but due to concomitant left ventricular dilata-
tion the global ejection fraction may not change. Fifty-
eight percent of the patients who were admitted with an
ejection fraction of less than 50% and who had suc-
cessful reperfusion had a significant increase in their
left ventricular ejection fraction by the time of hospital
discharge and it persisted for up to 6 months. The
factors that determine which patients will improve
with reperfusion are unknown. We suspect that only
direct measurement of cellular viability by a method
such as positron metabolic imaging will provide an
answer to this question.
In conclusion, intracoronary streptokinase therapy
during evolving myocardial infarction up to 18 hr after
the onset of chest pain was associated with improved
mean left ventricular performance compared with that
on admission. This was true at hospital discharge and
at 6 month follow-up. The improvement in function
was not seen in a comparable control group or in pa-
tients in whom reperfusion failed. Cardiac mortality
rate was significantly lower in the study group than in
the control group when patients in cardiogenic shock
or with pulmonary edema on admission were excluded
from both groups. Both survival and improvement in
left ventricular function appear to be related to the
success rate of coronary reperfusion in the treatment of
patients with acute myocardial infarction. A learning
curve may exist in the successful treatment of myocar-
dial infarction by intracoronary streptokinase adminis-
tration.
We thank Diane Bennett, Linda Parsel, Nancy Moratz, Beth
Killingsworth, and Ashok Desai for their technical assistance.
We also thank Salma Marani for assistance in statistical analysis
and Terrie Powell for preparing the manuscript.
References
1. Juergens JL, Edwards JE, Achor RW, Burchell HB: Prognosis of
patients surviving first clinically diagnosed myocardial infarction.
Arch Intern Med 105: 134, 1960
2. Pell S, D'Alonzo CA: Immediate mortality and five year survival
of employed men with a first myocardial infarction. N Engl J Med
270: 915, 1964
3. Goldberg RJ, Kennedy HL, Gore JM: Absence of secular changes
in the prognosis of patients with an initial myocardial infarction.
Clin Cardiol 5: 469, 1982
4. Howland JS, Vaillant HW: Long term survival of 224 patients with
myocardial infarction treated in a community hospital. J Family
Prac 10: 979, 1980
5. Phillips SJ, Kongtahworn C, Zeff RH, Benson M, lannone L,
Brown T, Gordon DF: Emergency coronary artery revasculariza-
tion: A possible therapy for acute myocardial infarction. Circula-
tion 60: 241, 1979
6. DeWood MA, Spores J, Notske RL, Lang HT, Shields JP, Simp-
son CS, Rudy LW, Grunwald R: Medical and surgical manage-
ment of myocardial infarction. Am J Cardiology 44: 1356, 1979
7. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering H,
Oster H, Leitz K: Acute myocardial infarction: intracoronary appli-
cation of nitroglycerin and streptokinase. Clin Cardiol 2: 354, 1979
8. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K:
Selective intracoronary thrombolysis in acute myocardial infarc-
tion and unstable angina pectoris. Circulation 63: 307, 1981
9. Reduto LA, Smalling RW, Freund GC, Gould KL: Intracoronary
infusion of streptokinase in patients with acute myocardial infarc-
tion: effects of reperfusion on left ventricular performance. Am J
Cardiol 48: 403, 1981
10. Reduto LA, Freund GC, Gaeta JM, Smalling RW, Lewis B, Gould
KL: Coronary artery reperfusion in acute myocardial infarction:
Beneficial effects of intracoronary streptokinase on left ventricular
salvage and performance. Am Heart J 102: 1168, 1981
11. Anderson JL, Marshall HW, Bray BE, Lutz JR, Frederick PR,
Klausner SC, Hagan AD: A randomized trial of intracoronary
streptokinase in acute myocardial infarction. Circulation 66 (suppl
II): 11-334, 1982
12. Mathey D, Sheehan FH, Schofer J, Bleifeld W, Dodge HT: LV
function following intracoronary thrombolysis in acute myocardial
infarction. Circulation 66 (suppl II): 11-335, 1982
13. Stack RS, Phillips HR, Grierson D, Kong Y, Peter RH, Behan VS:
Changes in segmental function ofjeopardized myocardium follow-
ing streptokinase infusion. Circulation 66 (suppl lI): 11-336, 1982
14. Aber CP, Bass NM, Berry CL, Carson PHM, Dobbs RJ, Fox KM,
Ham un JJ, Haydu SP, Howitt G, Maclver JE, Portal RW, Raftery
EB, Rousell RH, Stock JPP: Streptokinase in acute myocardial
infarction: a controlled multicentre study in the United Kingdom.
BrMedJ2: 1100, 1976
15. European Cooperative Study Group for streptokinase treatment in
acute myocardial infarction: Streptokinase in acute myocardial in-
farction. N Engl J Med 301: 797, 1979
16. Thanavoro S, Kleiger RE, Province MA, Hubert JW, Miller JP,
Krone RJ, Oliver GC: Effect of infarct location on the in-hospital
prognosis of patients with first transmural myocardial infarction.
Circulation 66: 742, 1982
17. Reduto LA, Berger HJ, Cohen LS, Gottschalk A, Zaret BL: Se-
quential Radionuclide asessment of left and right ventricular per-
formance after acute transmural myocardial infarction. Ann Intern
Med 89: 441, 1978
18. Shelbert HR, Henning H, Ashburn WL, Verba JW, Karliner JS,
O'Rourke RA: Serial measurements of left ventricular ejection
fraction by radionuclide angiography early and late after myocardi-
al infarction. Am J Cardiol 38: 407, 1976
19. Theroux P, Ross J, Franklin D, Kemper WS, Sasayama S: Coro-
nary arterial reperfusion III. Early and late effects on regional
myocardial function and dimensions in conscious dogs. Am J Car-
diol 38: 599, 1976
20. Constantino C, Corday E, Lang T, Meerbaum S, Brasch J, Kaplan
L, Rubins S, Gold H, Osher J: Revascularization after three hours
of coronary arterial occlusion: effects on regional cardiac metabolic
function and infarct size. Am J Cardiol 36: 368, 1975
21. Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML:
Regional Cardiac dilitation after acute myocardial infarction. N
Engl J Med 300: 57, 1979
CIRCULATION
138  by guest on July 26, 2016http://circ.ahajournals.org/Downloaded from 
R P Sterling and K L Gould
R W Smalling, F Fuentes, M W Matthews, G C Freund, C H Hicks, L A Reduto, W E Walker,
streptokinase administration during evolving myocardial infarction.
Sustained improvement in left ventricular function and mortality by intracoronary
Print ISSN: 0009-7322. Online ISSN: 1524-4539 
Copyright © 1983 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation 
doi: 10.1161/01.CIR.68.1.131
1983;68:131-138Circulation. 
 http://circ.ahajournals.org/content/68/1/131
the World Wide Web at: 
The online version of this article, along with updated information and services, is located on
  
 http://circ.ahajournals.org//subscriptions/
is online at: Circulation  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer information about this process is available in the
located, click Request Permissions in the middle column of the Web page under Services. Further
Editorial Office. Once the online version of the published article for which permission is being requested is 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not theCirculationpublished in
 Requests for permissions to reproduce figures, tables, or portions of articles originallyPermissions:
 by guest on July 26, 2016http://circ.ahajournals.org/Downloaded from 
